Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Accumulated Expenses (2019 - 2025)

Vivos Therapeutics has reported Accumulated Expenses over the past 7 years, most recently at $1.8 million for Q4 2025.

  • Quarterly Accumulated Expenses rose 84.12% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, up 84.12% year-over-year, with the annual reading at $1.8 million for FY2025, 84.12% up from the prior year.
  • Accumulated Expenses was $1.8 million for Q4 2025 at Vivos Therapeutics, down from $2.7 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $3.2 million in Q1 2022 and troughed at $1.0 million in Q4 2024.
  • The 5-year median for Accumulated Expenses is $2.0 million (2023), against an average of $2.0 million.
  • Year-over-year, Accumulated Expenses tumbled 58.92% in 2023 and then skyrocketed 84.12% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $1.4 million in 2021, then fell by 2.79% to $1.4 million in 2022, then soared by 71.87% to $2.3 million in 2023, then crashed by 57.11% to $1.0 million in 2024, then skyrocketed by 84.12% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Accumulated Expenses are $1.8 million (Q4 2025), $2.7 million (Q3 2025), and $2.3 million (Q2 2025).